Literature DB >> 8865208

The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system.

M K Matyszak1, V H Perry.   

Abstract

Dendritic cells of the rat were studied immunohistochemically with MRC OX62 monoclonal antibody and using electron microscopy. In normal CNS, a small number of OX62+ cells was detected in the choroid plexus and meninges. These cells were absent from other CNS and peripheral nervous system sites studied. Dendritic cells were also studied in two models of immune-mediated inflammatory conditions in the CNS. These were: acute experimental allergic encephalomyelitis and aberrant delayed-type hypersensitivity lesions induced as a response to heat-killed bacillus Calmette-Guérin sequestrated behind the blood-brain barrier. In addition, a group of animals with a delayed-type hypersensitivity response was treated with dexamethasone to assess the effect of steroid treatment on T-cells and OX62+ cells in CNS lesions. Dendritic cells were present in many but not all lesions in acute experimental allergic encephalomyelitis and their numbers were small. In experimental allergic encephalomyelitis lesions, dendritic cells were found predominantly in perivascular cuffs, where they constituted approximately 2% of the total number of major histocompatibility complex class II+ cells. Some of these cells were also detected in the CNS parenchyma, close to the perivascular cuff. In contrast, dendritic cells were present in all delayed-type hypersensitivity lesions studied. Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions. Numerous OX62+ cells were found, even in three-month-old lesions. Electron microscopy studies revealed that these cells were often in close contact with lymphocytes. There was no significant change in the density of OX62+ cells, IL2R+ cells and OX19+ T-cells in delayed-type hypersensitivity lesions after seven-day treatment with dexamethasone, although there was a considerable reduction in the number of CD45RA+ T-cells. The high numbers of dendritic cells found in the delayed-type hypersensitivity lesions may be important in contributing to the chronicity of the response. They may also initiate autoimmune responses to CNS antigens uncovered during bystander tissue damage which occurs as a consequence of aberrant delayed-type hypersensitivity responses.

Entities:  

Mesh:

Year:  1996        PMID: 8865208     DOI: 10.1016/0306-4522(96)00160-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  66 in total

1.  Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis.

Authors:  M Pashenkov; N Teleshova; M Kouwenhoven; V Kostulas; Y-M Huang; M Soderstrom; H Link
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.

Authors:  Benjamin D Clarkson; Erika Héninger; Melissa G Harris; JangEun Lee; Matyas Sandor; Zsuzsanna Fabry
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.

Authors:  Daniel Larocque; Nicholas S R Sanderson; Josée Bergeron; James F Curtin; Joe Girton; Mia Wibowo; Niyati Bondale; Kurt M Kroeger; Jieping Yang; Liliana M Lacayo; Kevin C Reyes; Catherine Farrokhi; Robert N Pechnick; Maria G Castro; Pedro R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

Review 4.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 5.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

6.  Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases.

Authors:  Alla L Zozulya; Emily Reinke; Dana C Baiu; Jozsef Karman; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

Review 7.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

8.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Authors:  Carlos Barcia; Maximiliano Jimenez-Dalmaroni; Kurt M Kroeger; Mariana Puntel; Alison J Rapaport; Daniel Larocque; Gwendalyn D King; Stephen A Johnson; Chunyan Liu; Weidong Xiong; Marianela Candolfi; Sonali Mondkar; Philip Ng; Donna Palmer; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

Review 9.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

10.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.